Seroclearance reduces the incidence of hepatocellular cancer (HCC) compared to virologically suppressed hepatitis B patients
In a retrospective study of patients with chronic hepatitis B on
suppressive treatment with entecavir or tenofovir, the incidence
of HCC was compared between those who cleared the virus
(negative hepatitis B surface antigen) and those on treatment
who did not clear the virus.